Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
FDA Office of Orphan Products Development Discovery Laboratories |
---|---|
Information provided by: | FDA Office of Orphan Products Development |
ClinicalTrials.gov Identifier: | NCT00004500 |
OBJECTIVES:
I. Determine the safety and efficacy of lucinactant in full term newborn infants with meconium aspiration syndrome.
Condition | Intervention | Phase |
---|---|---|
Meconium Aspiration |
Drug: Lucinactant |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Active Control, Single Group Assignment, Safety/Efficacy Study |
Estimated Enrollment: | 200 |
Study Start Date: | November 2000 |
PROTOCOL OUTLINE:
This is a randomized, multicenter study. Patients are randomized to one of two treatment arms.
Arm I: Patients receive lucinactant by bronchoalveolar lavage, into the right and left lung, followed by lung drainage. Treatment repeats when patient stabilizes or every 15 minutes for 2 courses.
Arm II: Patients receive standard treatment including oxygen, conventional mechanical ventilation, sedation, paralysis, vasopressors, and alkalinization.
Patients are followed for 12 months.
Ages Eligible for Study: | up to 2 Days |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics--
Diagnosis of meconium aspiration syndrome with respiratory distress and meconium staining at birth, in airways, or in bronchial secretions, in which there is no other major cause for respiratory distress
Conventional intermittent mandatory ventilation
At least 37 weeks gestational age
--Patient Characteristics--
Renal: No oligohydramnios with renal dysgenesis
Cardiovascular: No congenital cyanotic heart disease
Pulmonary: No airway anomalies; No lung hypoplasia; No pulmonary hemorrhage; No pulmonary interstitial emphysema, uncontrollable air leaks, pneumothorax, pneumomediastinum, or pneumopericardium; Oxygenation index at least 5 and no greater than 30 on a single arterial blood gas reading within 60 minutes prior to study; No diaphragmatic hernia
Neurologic: No known grade III or IV intraventricular hemorrhage; No obvious CNS abnormalities or malformations
Other: No hydrops fetalis immune and nonimmune; No prolonged (at least 3 weeks) rupture of the fetal membranes
United States, Pennsylvania | |
Discovery Laboratories, Inc. | |
Doylestown, Pennsylvania, United States, 18901 |
Study Chair: | Thomas E Wiswell | Discovery Laboratories |
Study ID Numbers: | 199/14367, ATI-FDR001424 |
Study First Received: | October 18, 1999 |
Last Updated: | January 4, 2008 |
ClinicalTrials.gov Identifier: | NCT00004500 |
Health Authority: | United States: Federal Government |
cardiovascular and respiratory diseases meconium aspiration syndrome rare disease |
Fetal Diseases Meconium Aspiration Syndrome Pregnancy Complications Respiratory Tract Diseases |
Lung Diseases Respiration Disorders Rare Diseases Infant, Newborn, Diseases |